Module 1 — Container/Carton/Patient Labeling (OBX-319)
📚 Part of the OBX-319 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.
This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing — the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.
What it is. Module 1 — Container/Carton/Patient Labeling (OBX-319)
Why it exists. Region-specific administrative content the agency requires in front of the scientific dossier.
How it is produced here. This is a region-specific administrative document, assembled to the local filing and labeling conventions. Its operational and label content is written to stay consistent with the (simulated) clinical data.
Format & governing standard. —
Module 1 — Container/Carton/Patient Labeling (OBX-319)
Document ID: M1-LBL
Version: 1.0
Change History: 1.0 — Initial issue.
Standard(s): 21 CFR 201/208; SPL
Container, Carton & Patient Labeling — OBX-319
The submission labeling set for OBX-319 beyond the prescribing information: immediate-container and carton labels (proprietary/nonproprietary name, strength, route [subcutaneous], storage, lot/expiry), a Medication Guide / Patient Package Insert, and, for the device presentation, Instructions for Use. In a US submission these are also provided as Structured Product Labeling (SPL) XML. 21 CFR 201; 208; SPL R8.
Comments (0)
No comments yet. Be the first to say something!